Core Viewpoint - The National Healthcare Security Administration (NHSA) has officially initiated the adjustment application process for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, along with a newly established commercial health insurance innovative drug catalog [1][2]. Group 1: Policy Implications - The inclusion of commercial health insurance in the national drug catalog system marks a significant breakthrough in China's multi-tiered medical security system, providing a regulatory foundation for commercial health insurance to enhance the accessibility of innovative drugs [5]. - The new commercial insurance catalog emphasizes a negotiation mechanism centered on information symmetry and professional support, which is crucial for collaboration between pharmaceutical companies and insurance providers regarding drug value recognition, pricing logic, and risk assessment [6]. Group 2: Innovative Drug Coverage - The "2025 China Innovative Drug and Medical Device Multi-Payment White Paper" indicates that currently, disease insurance accounts for 50% of commercial insurance payouts for innovative drugs, with million medical insurance at 22%, and other types making up the remainder [7]. - The key to designing products is to incorporate innovative drugs into a "sustainable protection structure" rather than treating them as merely high-priced medications [7]. Group 3: Recommendations for Improvement - Industry experts suggest focusing on three areas: introducing real-world evidence and stratified population data for better identification of payee groups, creating a combination of "basic insurance + commercial insurance + pharmaceutical company co-payment," and standardizing and automating the process from drug catalog to claims rules through a platform mechanism [7]. - There is a call for enhancing patient experience, process transparency, and claims efficiency as part of the catalog evaluation criteria to ensure that the catalog is accessible, implementable, and efficient in claims processing [8].

In this video, I explain why Oscar Health (OSCR -18.73%) crashed 18% on Wednesday and why I will buy shares. Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of July 2, 2025. The video was published on July 2, 2025. ...

美国与越南达成贸易协定。 市场概述 ADP全国就业报告显示，6月份私人部门就业人数减少了3.3万人，低于预期的增长9.8万人，5月份的增 幅被下调至2.9万人。ADP首席经济学家理查森（Nela Richardson）表示，公司在雇佣或更换员工方面 进展缓慢，但工资增长保持稳定。 人力资源机构Challenger，Gray&Christmas报道称，雇主在6月份宣布裁员47999人，大约是5月份的一 半，与去年同期相比变化不大。大多数公司将此归咎于广泛的经济压力，其中一些公司表示与关税有 关。 美国国债收益率上升，10年期利率上升4.3个基点至4.29%，2年期利率上涨1个基点至3.80%。联邦基金 利率期货显示， 7月份降息的概率从ADP报告前的约20%提高到25.3%。 Baird投资策略师梅菲尔德（Ross Mayfield）表示："我认为情况喜忧参半。一方面，工资仍然强劲，这 对美国经济非常重要。另一方面，如果这不是季节性的，而是白领工作长期趋势的开始，这将蔓延到整 个劳动力市场。这将对整体经济造成非常大的损害，显然会让美联储做出反应，尽管他们担心关税会导 致通货膨胀。" 现在市场焦点转向政府版非农就 ...

CANADA - 2025/04/06: In this photo illustration, the UnitedHealth Group logo is seen displayed on a ... More smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images UnitedHealth’s stock (NYSE:UNH) has undergone a noticeable decline, decreasing from a peak of around $600 in April to about $275 in May, and then making a slight recovery to $325. This drop followed the company’s announcement of disappointing Q1 results, the later ...

7月1日，业界期盼许久的两份重磅文件，终于发布亮相。 上午，国家医保局、国家卫健委联合印发的《支持创新药高质量发展的若干措施》（下称《若干措施》）挂网，明确将通过"协商"合理确定商保创新药目 录内药品结算价。 下午，《2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整工作方案》（下称《工作方案》）公开征求意见，制 定了价格协商的基本流程，但仍未确定具体细则。 无论如何，被热议大半年、备受瞩目的丙类目录，最终以"商业健康保险创新药品目录"（下称"商保创新药目录"）的名称正式官宣落地，国家医保局同步 明确第一版商保创新药目录的制定，将与2025年国谈同步进行。 至此，此前业界多次披露和猜测的关于商保创新药目录的部分信息，得以确认：不仅与国谈同步进行，药企还可采取"双轨申报"医保+商保的模式，即自 主选择申报纳入基本医保目录或纳入商业保险创新药目录，也可同时申报双目录。 而确认之外，还有一些较大的变化和政策的含蓄演变，一改市场此前预期。 变化主要集中在关于价格谈判、保司参与、政策落地等方面。过去一段时间，业界关心的核心问题有三：商保创新药目录会进行药品价格谈判？保司是否 参与谈判？ ...

两部门：增设商业健康保险创新药品目录 智通财经7月1日电，国家医保局、国家卫生健康委印发《支持创新药高质量发展的若干措施》，其中提 出，增设商业健康保险创新药品目录。适应多层次医疗保障体系发展需要，增设商业健康保险创新药品 目录（以下称商保创新药目录），重点纳入创新程度高、临床价值大、患者获益显著且超出基本医保保 障范围的创新药，推荐商业健康保险和医疗互助等多层次医疗保障体系参考使用。通过协商合理确定商 保创新药目录内药品结算价，探索更严格的价格保密机制。商保创新药目录内药品不计入基本医保自费 率指标和集采中选可替代品种监测的范围。统筹做好商保创新药目录与医保目录的衔接。 ...

国家医保局、国家卫生健康委印发《支持创新药高质量发展的若干措施》，其中提出，鼓励商业健康保 险扩大创新药投资规模。鼓励商业健康保险公司通过创新药投资基金等多种方式，为创新药研发提供稳 定的长期投资，培育支持创新药的耐心资本。 ...

南方财经全媒体记者 孙诗卉 上海报道 值得注意的是，公司面向用户推出一站式服务平台"一码直付"，整合药品、医疗、保险等资源，为用户 提供更多支付方案，实现医药直付。此前，镁信健康在接受21世纪经济报道记者采访时透露，该平台已 经实现了广域医院及药房全覆盖——可以覆盖两万多家二级及以上医院。同时，将保险产品种类拓宽到 中端医疗险、百万医疗险、惠民保和特药险等等，让普通商保参保客户也能享受保险直付服务。 6月30日，21世纪经济报道记者获悉，上海镁信健康科技集团股份有限公司（以下简称"镁信健康"或"公 司"）正式向香港联交所递交招股说明书，拟赴港上市。高盛（亚洲）、中金公司及汇丰银行担任联席 保荐人。 根据弗若斯特沙利文资料，以2024年平台支付总额（GPV）计算，镁信健康是中国最大的创新药械解决 方案提供商，同时以服务的保单数量计算，公司是规模最大的创新健康保险解决方案提供商。截至2024 年12月31日，公司累计服务保单数量约3.93亿，与超140家药企（包括按2024年收入计的全球前20大药 企中的90%）以及超90家保司（包括按2024年保费收入计的中国前20大保司的100%）达成合作。财务 数据显示，2 ...

Group 1 - UnitedHealth Group is accelerating its exit from the Latin American market, having received four non-binding offers for its Banmedica operations in Chile and Colombia, with a transaction value of approximately $1 billion [1] - The company has incurred over $8 billion in losses from its Latin American operations since initiating its exit plan in 2022, primarily due to ongoing losses from its Brazilian subsidiary, Amil, which led to a $7.1 billion impairment loss last year [1] - The new CEO, Steve Hemsley, faces significant pressure as the company's stock price plummeted 25.5% in May and has fallen 40% year-to-date, compounded by an ongoing criminal fraud investigation related to the previous CEO's management [1][2] Group 2 - The Banmedica asset has significantly depreciated since its acquisition, with insurance plan members decreasing from 2.1 million to 1.7 million and the hospital network shrinking from 13 to 7 facilities [2] - UnitedHealth Group acquired Banmedica at a high valuation of 12 times EBITDA in 2018, but continuous losses in Brazil forced the company to withdraw from the country entirely in 2023 [2] - The sale of Banmedica, advised by Brazilian investment bank BTG Pactual, is seen as a critical test for the new CEO's crisis management capabilities amid management turmoil and performance challenges [2]

Group 1 - The central government is set to establish a commercial health insurance innovative drug catalog to better meet the multi-level medication guarantee needs of the public [1] - The Ministry of Industry and Information Technology and the Ministry of Civil Affairs are promoting the design and development of intelligent elderly care service robots, with a pilot period from 2025 to 2027 [3] - The Ministry of Housing and Urban-Rural Development aims to achieve an average resource utilization rate of over 50% for construction waste in cities at the prefecture level and above by 2027 [6] Group 2 - The Beijing Municipal Bureau of Commerce is planning to create a global first-release center to support the renovation and upgrading of commercial districts and shopping malls [8] - The State Administration for Market Regulation has issued compliance guidelines for the "6·18" online promotional event, emphasizing fair market competition and the prevention of illegal activities [10] - Guiyang is establishing a joint meeting system to promote the development of the sports industry, with plans to introduce supportive policies and funding for sports products and services [11]